Advertisement

---

RXI PHARMACEUTICALS CORPORATION

RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109

[2013-06-06] - RXI-109 was well tolerated and produced a statistically significant and dose dependent reduction of Connective Tissue Growth Factor (CTGF), a protein that causes abnormal scarring when it is over-expressed in a wound


RXi Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

[2013-05-20] -


RXi Pharmaceuticals to Present at IBC's 15th Annual TIDES: Oligonucleotide and Peptide Therapeutics Conference

[2013-05-09] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers